Avalyn Pharma
AVLN
25.53
+0.10
+0.39%
Avalyn Pharma
US · AVLN
#3161 by market cap
Listed 2026
25.53
+0.10
+0.39%
Live - 5344 symbols - heartbeat 263s ago
· 2026-10-08 04:12
Pre-market
25.98
+1.74%
After-hours
25.53
0.00%
- Market cap
- 1.13B
- P/E (TTM)i
- -10.96
- P/Bi
- 2.84
- EPSi
- -2.04
- Div yieldi
- 0.00%
- 52W posi
- 9%
Reader sentiment
Are you bullish or bearish on AVLN?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 2 years
Income statement
| Line item | 2024 | 2025 |
|---|---|---|
| Revenue | -- | -- |
| Gross profit | -- | -- |
| Selling & admin expenses | 11.36M | 14.68M |
| Research & development | 45.76M | 76.61M |
| Operating profit | -57.12M | -91.29M |
| Pretax profit | -49.74M | -85.20M |
| Tax | -- | -- |
| Net profit | -49.74M | -85.20M |
| Basic EPS | -1 | -2 |
| Diluted EPS | -1.19 | -2.04 |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| Revenue | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- |
| Selling & admin expenses | 3.40M | 3.90M | 5.02M | 6.56M |
| Research & development | 15.32M | 17.88M | 22.89M | 24.73M |
| Operating profit | -18.72M | -21.78M | -27.91M | -31.29M |
| Pretax profit | -17.50M | -20.19M | -26.87M | -28.94M |
| Tax | -- | -- | -- | -- |
| Net profit | -17.50M | -20.19M | -26.87M | -28.94M |
| Basic EPS | 0 | 0 | -1 | -1 |
| Diluted EPS | -0.42 | -0.48 | -0.64 | -0.65 |
Balance sheet
| Line item | 2024 | 2025 |
|---|---|---|
| Total current assets | 114.39M | 143.56M |
| Cash & ST investments | 110.63M | 138.36M |
| Inventory | -- | -- |
| Total assets | 124.52M | 148.88M |
| Total current liabilities | 8.74M | 14.09M |
| Short-term debt | -- | 444.00K |
| Long-term debt | -- | -- |
| Total liabilities | 299,041,000.00 | 387,537,000.00 |
| Total equity | -174.52M | -238.66M |
| Retained earnings | -180.16M | -265.36M |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| Total current assets | -- | -- | 129.99M | 357.99M |
| Cash & ST investments | -- | -- | 123.13M | 352.43M |
| Inventory | -- | -- | -- | -- |
| Total assets | -- | -- | 135.66M | 425.45M |
| Total current liabilities | -- | -- | 11.79M | 10.81M |
| Short-term debt | -- | -- | 507.00K | 816.00K |
| Long-term debt | -- | -- | 14.81M | 14.80M |
| Total liabilities | -- | -- | 399,908,000.00 | 27,102,000.00 |
| Total equity | -- | -- | -264.25M | 398.35M |
| Retained earnings | -- | -- | -292.23M | -321.17M |
Cash flow
| Line item | 2024 | 2025 |
|---|---|---|
| Operating cash flow | -48.37M | -81.48M |
| Depreciation & amortization | 29.00K | 42.00K |
| Free cash flow | -48.46M | -81.83M |
| Dividends paid | -- | -- |
| Stock buybacks / issuance | -- | -- |
| Ending cash balance | 23.96M | 52.32M |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| Operating cash flow | -19.28M | -20.70M | -29.89M | -26.08M |
| Depreciation & amortization | 10.00K | 9.00K | 63.00K | 110.00K |
| Free cash flow | -19.28M | -20.70M | -30.21M | -26.35M |
| Dividends paid | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- |
| Ending cash balance | 28.80M | 61.30M | 92.31M | 264.20M |
Returns & efficiency
| Line item | 2024 | 2025 |
|---|---|---|
| ROE %i | -- | -- |
| ROA %i | -39.95 | -62.33 |
| ROIC %i | -- | -- |
| 5-year avg ROE %i | -- | -- |
| EBIT margin %i | -- | -- |
| FCF / sales %i | -- | -- |
| Current ratioi | 13.08 | 10.19 |
| Quick ratioi | 12.72 | 9.86 |
| Debt / assetsi | 0.00 | 1.12 |
| LT debt / equityi | -- | -- |
| Interest coveragei | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- |
| Net income CAGR (3Y) %i | -- | -- |
| FCF CAGR (3Y) %i | -- | -- |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| ROE %i | -- | -- | -- | -25.94 |
| ROA %i | -- | -- | -69.71 | -24.28 |
| ROIC %i | -- | -- | -- | -26.58 |
| 5-year avg ROE %i | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- |
| Current ratioi | -- | -- | 11.03 | 33.12 |
| Quick ratioi | -- | -- | 10.47 | 32.76 |
| Debt / assetsi | -- | -- | 12.09 | 4.02 |
| LT debt / equityi | -- | -- | -- | 4.09 |
| Interest coveragei | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- |
Quote time 2026-10-08 04:12:40 · For reference only, not investment advice and not tailored to your situation.